The findings that Fyn activation is not restricted to AD patients appeared consistent with previous evidence, pointing to the involvement of Fyn in a multitude of processes related either to cellular functions or dysfunctions [13] and strengthening the importance to confine any potential treatments with Fyn TKI to those patients in which APP Tyr682 phosphorylation levels are elevated. This evidence concerns the gene FYN and Alzheimer disease.